PACIRA BIOSCIENCES, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value
PACIRA BIOSCIENCES, INC. (PCRX) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value of $10.25 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue · last filed 2026-08-04
- 2026-06-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $10.25M.
- 2026-03-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $10.25M.
- 2025-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $10.25M.
- 2025-09-30: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value $10.25M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value |
|---|---|
| 2026-06-30 | $10.25M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $10.25M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $10.25M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $10.25M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $10.25M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $20.00M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $27.77M 10-Q · filed 2026-08-04 |
| 2024-09-30 | $28.03M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $27.87M 10-Q · filed 2024-07-30 |
| 2024-03-31 | $27.91M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $28.01M 10-K · filed 2026-02-26 |
| 2023-09-30 | $27.82M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $27.94M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $25.21M 10-Q · filed 2023-05-03 |
| 2022-12-31 | $21.19M 10-K · filed 2025-02-27 |
| 2022-09-30 | $21.10M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $30.93M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $30.99M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $18.26M 10-K · filed 2024-02-29 |
| 2020-12-31 | $12.80M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |